Dyslipidemia, Central Belly Fat and Sugar

[Mishma]

Good accessible review of the metabolic effects of HIV and the drugs we take. The entire article is available free of charge. Below the abstract. I would personally like to see the drug Festinavir and other NRTIs that do not interfere with mitochondrial DNA polymerases in phase III trails. Now that I'm off of the protease inhibitors I'll be curious to see if I experience any body changes.

Published in final edited form as:
Nat Rev Endocrinol. ; 8(1): 11–21. doi:10.1038/nrendo.2011.151.
Management of the metabolic effects of HIV and HIV drugs
Todd T. Brown and
Division of Endocrinology and Metabolism, Johns Hopkins University, 1830 East Monument Street, Baltimore, MD 21287, USA
Marshall J. Glesby
Division of Infectious Diseases, Weill Cornell Medical College, 525 East 68th Street, New York, NY 10021, USA
Abstract
Morphologic and metabolic abnormalities, including subcutaneous adipose tissue wasting, central adipose tissue accumulation, dyslipidemia and disorders of glucose metabolism are common among HIV-infected patients receiving highly active antiretroviral therapy (HAART) and contribute to the risk of cardiovascular disease in this population. The pathogenesis of these disorders is due to complicated interactions between effects of chronic HIV infection, HAART medications, and patient factors, including genetic susceptibility. HAART has transformed HIV into a chronic condition for many patients and as a result the majority of HIV-infected patients in many areas of the developed world are ≥50 years. Since metabolic and cardiovascular diseases increase with aging, knowledge of the optimal management of these conditions is essential for practitioners caring for HIV-infected patients, including endocrine subspecialists. This Review highlights the clinical management of these disorders, focusing on the most recent evidence regarding the efficacy of treatment strategies, newly available medications and potential interactions between HAART medications and medications used to treat metabolic disorders.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371609/pdf/nihms381084.pdf